MacroGenics

MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MacroGenics reports revenue growth and promising clinical updates in Q4

MacroGenics delivered strong financial performance with revenue growth and cost reductions in 2022.
The company faces challenges in study modifications, dose optimization, and patient evaluation for its key products.
Opportunities lie in expanding product studies, strategic partnerships, and optimizing treatment efficacy.
Overall, MacroGenics shows promise in financial stability, product development, and market positioning.

MacroGenics reports Q1 revenue growth amidst net loss challenges

MacroGenics showed mixed financial performance in Q1 2023 with revenue growth but a significant net loss.
The company's strengths lie in its anticipated cash runway, FDA approvals, and expected milestone payments.
Challenges include managing expenses, improving financial performance, and addressing analyst inquiries.
Opportunities exist in revenue growth, clinical programs, FDA approvals, and strategic partnerships.

MacroGenics reports Q2 results, projects strong pipeline growth ahead

MacroGenics' Q2 2023 performance reflects mixed financial results but strong progress in pipeline development and strategic partnerships.
The company's financial stability, ongoing innovation, and revenue potential position it well for future growth and value creation.
Challenges in data disclosure, enrollment criteria, and dose optimization require careful navigation, but present opportunities for market expansion and program enhancement.

MacroGenics reports improved Q3 earnings, eyes strategic partnerships for growth

MacroGenics demonstrated improved financial performance in Q3 2023, with a focus on cost management and strategic pipeline advancements.
The company's efforts to secure non-dilutive capital, explore partnerships, and drive innovation in ADC development position it for future growth.
Challenges lie in revenue generation, market differentiation, and resource allocation, but opportunities exist in collaborations, tumor type expansion, and technological advancements.

MacroGenics reports revenue decline but advances in clinical programs

MacroGenics faced a decline in revenue but made progress in its clinical programs and pipeline advancements.
Challenges include data transparency, patient enrollment, and managing treatment side effects.
Opportunities lie in potential Phase III trials, revenue growth prospects, and advancements in patient treatment.

MacroGenics reports strong Q1 results, eyes expansion and combination therapies

MacroGenics' Q1 2024 performance showed promising results with strong revenue and ongoing research advancements.
The company's focus on expanding studies, improving tolerability, and exploring combination therapies presents growth opportunities.
Challenges include ongoing investigations into safety protocols and evaluation of patient outcomes.
Overall, MacroGenics' strategic plans and positive efficacy outcomes position them well for future growth and development.

MacroGenics reports stellar Q3 earnings, CEO transition announced

MacroGenics delivered impressive financial results in Q3 2024, marked by substantial revenue growth, increased net income, and a solid cash balance supported by strategic initiatives.
While facing challenges in managing rising expenses and navigating a CEO transition, the company's diverse clinical pipeline and strong financial position present opportunities for future growth and innovation.
Investors should monitor how MacroGenics addresses cost management, sustains operational momentum during leadership changes, and capitalizes on its strengths to drive continued success in the biopharmaceutical sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Rockville, MD, Nov.  07, 2019  (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will attend the following investor conferences in November:

MacroGenics  to Participate in Upcoming Investor Conferences.

MacroGenics (MGNX) delivered earnings and revenue surprises of 4.21% and -19.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates

ROCKVILLE, MD, Nov.  06, 2019  (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the clinical and preclinical abstracts related to flotetuzumab, the Company’s investigational bispecific CD123 x CD3 DART® molecule, to be presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida, from December 7-10, 2019.

MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019

GW Pharmaceuticals

Insulet

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

3 'Medical Product' Stocks Likely to Beat This Earnings Season

MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MacroGenics (MGNX) Expected to Beat Earnings Estimates: Should You Buy?

Merus

Seagen

Zymeworks Inc

With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.

4 Stocks Battling Breast Cancer

Rockville, MD, Oct.  25, 2019  (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the first patient has been dosed in the Phase 2/3 MAHOGANY clinical trial of margetuximab, an investigational, Fc-optimized monoclonal antibody targeting HER2, in combination with a checkpoint inhibitor, with or without chemotherapy, as a potential first-line treatment for patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.

MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer

Shares sink after the company provides investors with a clinical update. Here are the must-know details.

Why MacroGenics Is Tanking Today

ROCKVILLE, MD, Oct.  22, 2019  (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced topline results from the second pre-specified interim overall survival (OS) analysis for the Phase 3 SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies. Margetuximab is an investigational, immune-enhancing monoclonal antibody derived from the Company’s proprietary Fc Optimization technology platform.

MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

ROCKVILLE, MD, Sept.  30, 2019  (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced updated results from a Phase 2 study of margetuximab, an investigational, Fc-optimized monoclonal antibody targeting HER2, plus pembrolizumab, an anti-PD-1 monoclonal antibody, in a chemotherapy-free regimen that is designed to engage innate and adaptive immunity, for patients with advanced HER2-positive gastroesophageal adenocarcinoma (GEA) who have previously been treated with chemotherapy and trastuzumab in the metastatic setting. Data were presented at the European Society for Medical Oncology (ESMO) Annual Congress 2019.

MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress

MacroGenics produced decent phase 3 data in third line metastatic breast cancer from the SOPHIA trial.

MacroGenics: Decent Data, Strong Cash, Upcoming Catalysts, One Risk

ROCKVILLE, MD, Sept.  26, 2019  (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the 2019 Cantor Global Healthcare Conference in New York City in a fireside chat on Thursday, October 3, 2019, at 9:30 a.m. ET.

MacroGenics to Participate in Cantor Global Healthcare Conference

ROCKVILLE, MD, Aug.  29, 2019  (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will attend the following investor conferences in September:

MacroGenics (MGNX) to Participate in Upcoming Investor Conferences

The stock has gained 35% since February, following the positive Phase 3 SOPHIA data release.

MacroGenics: Strong Fundamentals Coupled With Major Catalysts Ahead

MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q2 2019 Results - Earnings Call Transcript

Treatment for HER2-positive breast cancer represents a market opportunity of $10 billion in 2025 only in the US.

MacroGenics: Margetuximab's Potential Makes It Massively Undervalued

Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.

Implied Volatility Surging for MacroGenics (MGNX) Stock Options

Positive data on margetuximab in the treatment of HER2+ metastatic breast cancer propelled the stock 130% higher in one day of trading in early February.

MacroGenics: Updating The Investment Thesis

Genomic Health

Illumina

These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.

Three Cancer Treatment Stocks to Buy Right Now

Agios Pharmaceuticals

Iovance Biotherapeutics

Mirati Therapeutics

The 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) is scheduled for May 31 to June 4 in Chicago.

Thursday’s Top 4 ASCO Movers

MacroGenics shares jumped in response to another major clinical update today.

Why MacroGenics, Inc. Stock Is Heating Up Today

Looking ahead to the week of May 31 to June 4, one of the biggest health care conferences of the year, the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) takes place in Chicago.

Solid Breast Cancer Results From MacroGenics Ahead of ASCO

MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q1 2019 Results - Earnings Call Transcript

News for MacroGenics Stock (MGNX)